RT Journal Article
T1 The Coronavirus disease 2019 (COVID-19): key emphasis on melatonin safety and therapeutic efficacy
A1 Ramos, Eva
A1 López Muñoz, Francisco
A1 Gil Martin, Emilio
A1 Egea, Javier
A1 Álvarez Merz, Iris
A1 Painuli, Sakshi
A1 Semwal, Prabhakar
A1 Martins, Natália
A1 Hernández Guijo, Jesús M.
A1 Romero, Alejandro
K1 2412 Inmunología
K1 2420 Virología
K1 2302 Bioquímica
AB Viral infections constitute a tectonic convulsion in the normophysiology of the hosts. The current coronavirus disease 2019 (COVID-19) pandemic is not an exception, and therefore the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, like any other invading microbe, enacts a generalized immune response once the virus contacts the body. Melatonin is a systemic dealer that does not overlook any homeostasis disturbance, which consequently brings into play its cooperative triad, antioxidant, anti-inflammatory, and immune-stimulant backbone, to stop the infective cycle of SARS-CoV-2 or any other endogenous or exogenous threat. In COVID-19, the corporal propagation of SARS-CoV-2 involves an exacerbated oxidative activity and therefore the overproduction of great amounts of reactive oxygen and nitrogen species (RONS). The endorsement of melatonin as a possible protective agent against the current pandemic is indirectly supported by its widely demonstrated beneficial role in preclinical and clinical studies of other respiratory diseases. In addition, focusing the therapeutic action on strengthening the host protection responses in critical phases of the infective cycle makes it likely that multi-tasking melatonin will provide multi-protection, maintaining its efficacy against the virus variants that are already emerging and will emerge as long as SARS-CoV-2 continues to circulate among us.
PB Antioxidants
SN 20763921
YR 2021
FD 2021-07-20
LK http://hdl.handle.net/11093/2965
UL http://hdl.handle.net/11093/2965
LA eng
NO Antioxidants, 10(7): 1152 (2021)
NO UCJC | Ref. NEWTHERMEL: UCJC 2019-02
DS Investigo
RD 09-dic-2023